<DOC>
	<DOC>NCT02600507</DOC>
	<brief_summary>The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.</brief_summary>
	<brief_title>Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>male or female subjects of any race, ages 1875 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder experiencing a current major depressive episode treatment with either lithium or valproate and inadequate therapeutic response of depressive symptoms any subject unable to provide informed consent any female subject who is pregnant or breastfeeding any subject judged to be medically inappropriate for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>